If the interaction between EPN3 and EGFR can be interfered with by designing peptides through the binding site and the degradation of EGFR can be promoted, this may present a promising avenue for clinical treatment and drug development in NSCLC, particularly for TKI-resistant patients. This evidence concerns the gene EPN3 and non-small cell lung carcinoma.